Sorafenib, sunitinib may pose cardiovascular risk
(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.
Oct 13, 2015
0
7